Abstract
Importance of the field: In spite of the recent progress, the prognosis of acute myelogenous leukemia (AML) remains poor, particularly in patients with relapsed disease and in the elderly. In these situations, there is at present no standard of care, and new drugs are urgently needed. Areas covered in this review: Preclinical and clinical studies of Laromustine (formerly cloretazine, VNP-40101M), a new sulfonylhydrazine alkylator, in AML published between 2000 and September 2009 are presented and discussed. What the reader will gain: Mechanisms of action of Laromustine and preclincal data that support the rationale for its use in patients with AML are summarized. Laromustine has limited extramedullary toxicity. In Phase II studies, it produced 32% complete responses in elderly patients with previously untreated AML. In a Phase III comparative study of its combination with cytarabine in relapsed AML, increased response rate was offset by excessive toxicity. Take home message: Laromustine has significant activity in AML. As a single agent, laromustine may represent an alternative to conventional treatments for elderly patients. Although significant activity was seen, safety and optimal dosing in combination regimen remain to be established and are now being investigated.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 657-667 |
| Number of pages | 11 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 11 |
| Issue number | 4 |
| DOIs | |
| State | Published - Mar 2010 |
Funding
Taylor PR, Reid MM, Stark AN, et al. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. Leukemia 1995;9:231-7 Burnett AK, Eden OB. The treatment of acute leukaemia. Lancet 1997;349:270-5 Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988;2:403-12 Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995;9:1491-8 Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998;92:2322-33 Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adults acute myeloid leukemia: a Southwest Oncology
Keywords
- Acute myeloid leukemia
- Alkylating agents
- Elderly
- Induction chemotherapy
- Myelodysplastic syndrome
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
